Study: Drug has long-term survival benefit for some lung cancer patients
The results of a large global study show even a tiny amount of a biomarker known as PD-L1 can predict a long-term survival benefit from using pembrolizumab.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
More News: Cancer | Cancer & Oncology | Health | Lung Cancer | Science | Study | Universities & Medical Training | Yale